Know Cancer

or
forgot password

A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer


Phase 2
20 Years
N/A
Open (Enrolling)
Both
Metastatic Breast Cancer

Thank you

Trial Information

A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer


Inclusion Criteria:



- histologically proved breast cancer with metastatic disease

Exclusion Criteria:

- life expectancy less than 3 months.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Principal Investigator

Hsien-Kun Chang

Investigator Role:

Principal Investigator

Investigator Affiliation:

Chang Gung Memorial Hospital, Lin-Kou Medical Center

Authority:

Taiwan: Department of Health

Study ID:

LD0411

NCT ID:

NCT01451580

Start Date:

September 2005

Completion Date:

Related Keywords:

  • Metastatic Breast Cancer
  • Phase II
  • Metastatic Breast Cancer
  • Breast Neoplasms

Name

Location